Congress | GenomeWeb


The US House of Representatives has passed the latest version of the 21st Century Cures Act.

With strong bipartisan support, the White House indicated that President Barack Obama will sign the legislation once it receives Senate approval.

Eric Dishman, Director, All of Us Research Program

NIH has been conservative on the PMI's budget and its funds are sufficient to launch enrollment next year, begin collecting data, and initiate genetic testing pilot projects.

Up For a Vote, Again

The US 21st Century Cures Act is set to go up for a vote, though still with some points of contention.

The US House of Representatives is expected to vote on the sweeping biomedical funding legislation this Wednesday.

Personalized medicine proponents are uncertain where funding, personnel, and priorities will land in a new administration and Congress.

FierceBiotech says that a section at President-Elect Donald Trump's transition webpage could bode well for biotech.

Researchers working in the US tell Nature News that they are concerned about what a Trump presidency will mean for science.

The bill comes amid questions about the efficacy of Epigenomics' Epi proColon, the only blood-based cancer screening test approved in the US.

The bill, which would boost NIH funding among other things, was overwhelmingly approved by the House and cleared a Senate subcommittee, but has stalled amid negotiations over appropriations.


In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.